Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. Results of a controlled trial
Martin M, Diaz-Rubio E, Casado A, López Vega JM, Sastre J, Almenarez J
American journal of clinical oncology · 29 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 1992-08-01 · Am J Clin Oncol · vol. 15 · número 4 · págs. 348–351
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 52 citas · más que el 2% de estudios similares · 0.0× el promedio de su campo
- Referencias
- 0 trabajos
- Acceso
- De pago
- Áreas de investigación
- Magnesium in Health and Disease · Chemotherapy-induced organ toxicity mitigation · Magnesium Oxide Properties and Applications
- Palabras clave
- cisplatin, hypomagnesemia, magnesium supplementation, intravenous magnesium, oral magnesium, magnesium sulfate, chemotherapy side effects, prophylaxis, gastrointestinal adverse effects
- MeSH
- humans, neoplasms, magnesium deficiency, cisplatin, magnesium, administration, oral, infusions, intravenous, adult, aged, middle aged, female, male
6 autores
- Miguel Martín🇪🇸Hospital Clínico San Carlos
- Eduardo Díaz‐Rubio🇪🇸Hospital Clínico San Carlos
- Antonio Casado🇪🇸Hospital Clínico San Carlos
- José Manuel López Vega🇪🇸Hospital Clínico San Carlos
- Javier Sastre🇪🇸Hospital Clínico San Carlos
- J. Almenarez🇪🇸Hospital Clínico San Carlos
Resumen
El texto original del estudio, en el idioma en que se publicó.
The effects of oral and intravenous magnesium supplementation on cisplatin (CDDP)-induced hypomagnesemia were investigated in 41 patients treated with 100 mg/m2 CDDP. Patients were randomly allocated to receive no magnesium supplementation, intravenous magnesium supplementation (magnesium sulphate, 3 g before each CDDD administration) or oral magnesium supplementation (magnesium pidolate, 2 g orally every 8 hours on days 2 to 21 of each CDDP course) during the first 4 courses of CDDP treatment. Patients in both supplementation arms showed significantly higher magnesium levels than control patients from the second course on (oral magnesium arm) or from the third course on (intravenous magnesium arm). Three of the 9 patients (33%) in the intravenous magnesium arm and 4 of the 9 (44%) in the oral magnesium arm developed hypomagnesemia after the fourth course of CDDP, compared with 9 of the 10 (90%) unsupplemented patients. There were no magnesium-related side effects in patients on intravenous magnesium supplementation. Two patients treated with oral magnesium developed mild gastrointestinal symptoms (emesis and diarrhea), probably from magnesium therapy. Our study showed that both intravenous and oral magnesium supplementations appear to be safe and efficacious in the prevention of CDDP-induced hypomagnesemia. Since patients were not completely protected, and since the analysis was limited to the first four courses of chemotherapy, additional studies are needed to determine the best schedule of magnesium supplementation, especially in patients who receive more than four courses of CDDP chemotherapy.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.